Skip to Content

Merck & Co Inc

MRK: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$349.00TghzNjxbfwyz

Merck Posts Strong Q3 With Broad Portfolio Support, Leading to Slight Fair Value Estimate Increase

Merck reported strong third-quarter results ahead of our projections, and we plan to slightly raise our fair value estimate. Strong and largely broad-based growth supported 14% operational growth excluding COVID-19 sales from Lagevrio. The strong portfolio of branded drugs along with a developing pipeline continues to support Merck’s wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center